Astute Medical

Astute Medical

Based: San Diego
Raised: $40.45 million
Investors: De Novo Ventures, Delphi Ventures, Domain Associates, Johnson & Johnson Development Corporation, Kaiser Permanente Ventures, MPM Capital

The scoop: This was Astute's third round. The diagnostics company has big plans to start commercialization of its first product. And there are other diagnostic tests in the pipeline that will need further development, reports FierceMedicalDevices. The life sciences company intends to roll out a lineup of tests hospitals will be able to use to assess a slate of symptoms, like abdominal pain and kidney injury. Investors had already put in close to $33 million when the Series C came together. 

Astute Medical
Read more on

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.